Catalyst Wire Dossier Catalyst Wire Dossier

Besifloxacin ophthalmic suspension 0.6%

besifloxacin · Bausch & Lomb Incorporated
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Besifloxacin ophthalmic suspension 0.6%, covering 2014-09-17 to 2014-09-17. Get the full timeline:

Most recent: Clinical Trial Update: Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis [Phase 3]

See pricing